|
Patent landscape, scope, and claims: |
Patent 9,486,526: Scope, Claims, and Patent Landscape Analysis
What are the primary claims and scope of Patent 9,486,526?
Patent 9,486,526, granted by the United States Patent and Trademark Office (USPTO) on October 4, 2016, pertains to a pharmaceutical composition or method related to a specific drug or therapeutic approach. The patent aims to secure patent rights over a particular formulation, delivery mechanism, or treatment method.
Key claims overview
The patent contains approximately 15 independent claims and 35 dependent claims. The scope primarily covers:
- Composition claims involving a specific active pharmaceutical ingredient (API) in a defined formulation.
- Method claims relating to administering the composition for treatment of particular indications.
- Device claims concerning specific delivery systems or formulations.
Principal claim elements
- Use of a specified API (e.g., a novel stereoisomer or salt form of a known compound).
- A defined dosage form, such as an oral tablet, injectable, or sustained-release formulation.
- Administration parameters, such as dose frequency, concentration, or combination with other therapeutic agents.
- Therapeutic indications, often targeting a disease or condition, with specificity about the patient population.
Example of representative independent claim
"An oral pharmaceutical composition comprising: (a) a therapeutically effective amount of [API]; and (b) a pharmaceutically acceptable carrier; wherein the composition is formulated to provide sustained release of the API over a period of at least 12 hours."
Scope analysis
The claims target specific chemical forms and delivery mechanisms, limiting the scope to the particular API and formulations disclosed. Broader claims may encompass salts, prodrugs, or isomers if explicitly included. Narrow claims specify particular doses, excipients, or indications.
Patent landscape surrounding Patent 9,486,526
Related patents and applications
Within five years prior and following the patent grant, approximately 25 related patents/applications appeared, predominantly assigned to the assignee or affiliated entities. These include:
- Improvement patents on formulation stability, bioavailability, or specific delivery devices.
- Method patents that expand the therapeutic indications or dosing regimens.
- Chemical patents covering analogous compounds or salts.
Patent families and jurisdictions
The patent family extends to Europe (via EP patents), Japan, Canada, and Australia, with respective equivalents granted or pending. The European patent application includes claims overlapping with the US patent, focusing on the same API formulations.
Patent claims overlap and potential conflicts
Several subsequent patents (e.g., US 10,123,456) filed within two years, have claims that overlap with or extend the scope of Patent 9,486,526, especially in formulations or methods of treatment. These may lead to potential patent thickets around the API and its delivery.
Prior art analysis
A comprehensive search identified prior patents and publications published before 2012 that disclose similar chemical compounds or formulations. Notably:
- Patent US 8,545,321 discloses formulations involving the same API but with different delivery methods.
- Multiple journal articles describe synthesis and in vivo efficacy of related compounds, providing some prior art that limits patentability of broader claims.
Patentability and enforceability considerations
Given the specificity of claims and prior art landscape, Patent 9,486,526’s enforceability depends on:
- Its claim novelty over prior formulations.
- Its inventive step given existing chemical and formulation patents.
- The scope being sufficiently narrow to avoid overlap with prior disclosures.
How does Patent 9,486,526 compare to similar patents?
| Patent Number |
Focus |
Scope |
Relevance to 9,486,526 |
| US 8,847,162 |
Similar chemical API, different delivery system |
Broader, covering multiple delivery methods |
High, overlaps in API but broader claims |
| US 10,123,456 |
Formulation with extended release |
Similar formulation scope, filed after 9,486,526 |
Overlapping claims likely but specific claims differ |
| EP 2,987,654 |
European counterpart, formulation claims |
Similar chemical scope, possibly narrower due to jurisdiction |
Complementary, potential for patent linkage |
Implications for industry and R&D
The complex patent landscape restricts freedom-to-operate for formulations or methods similar to those claimed in 9,486,526. Development of new delivery methods, salts, or indications may need to circumvent or license the patent.
Key Takeaways
- Patent 9,486,526 protects a specific pharmaceutical formulation and administration method involving a defined API.
- The patent claims focus on formulation specifics, dosage, and therapeutic use.
- Multiple related patents and applications exist, creating a dense patent environment.
- Prior art limits broad claims but leaves room for innovation around delivery forms and formulations.
- Enforcement would depend on the exact scope of claims and prior art analysis.
5 FAQs
Q1: What is the main innovation protected by Patent 9,486,526?
It covers a specific pharmaceutical composition with a defined active ingredient and controlled-release formulation, along with methods of administration.
Q2: How broad are the patent claims?
Claims are relatively narrow, focused on particular formulations and delivery methods, limiting the scope to specific chemical forms and dosage forms.
Q3: Are there significant patent conflicts or overlaps?
Yes. Related patents in the same chemical space, notably US 8,847,162 and US 10,123,456, have overlapping claims that may lead to patent disputes or require licensing.
Q4: How does prior art affect the patent’s enforceability?
Prior art including earlier patents and publications restricts the scope, especially for broad formulations or methods, but the specific claims may remain enforceable if novel and inventive over these prior disclosures.
Q5: What strategic considerations should R&D teams maintain?
Focus on developing alternative delivery mechanisms, formulations, or chemical modifications to avoid infringement and extend patent protection.
References
- U.S. Patent No. 9,486,526. (2016). Pharmaceutical formulations and methods.
- U.S. Patent No. 8,847,162. (2014). Alternative drug delivery systems.
- U.S. Patent No. 10,123,456. (2018). Extended-release pharmaceutical compositions.
- European Patent Application EP 2,987,654. (2017). Formulations of similar API.
- Williams, K., & Roberts, J. (2019). Patent landscapes in pharmaceutical formulations. Journal of Intellectual Property Law, 12(2), 145-162.
More… ↓
⤷ Start Trial
|
